Searched for
RA CHEM PHARMA
Pharma raw material makers in race to tank up on CXO talentSome of these PE-owned platform companies include Advent International-led Cohance Lifesciences / Suven Pharma, PAG and CX Partners-funded ...- ADIA, HarbourVest eye minor stake in CohanceADIA and HarbourVest are in discussions to acquire a minority stake in Cohance Lifesciences, a pharmaceuticals platform owned by Advent Int...
- US-based Advent seeking investors for Suven-Cohance mergerAdvent announced its acquisition of Suven Pharma in December. Including the cost of the open offer, the deal size would go up to Rs 9,589 c...
- Advent International buys Suven Pharma for Rs 6,313 croreAdvent will also launch an open offer for an additional 26% of the company, a listed contract research and manufacturing services (CRAMS) b...
- Suven Pharma falls 2% as Advent picks majority stake in the companyPost the completion of this acquisition, Advent intends to explore the merger of its portfolio company, Cohance Lifesciences with Suven, to...
- Advent pips Blackstone, set to buy Suven Pharma for Rs 6300 crMarket capitalisation of Suven Pharma, as on Friday, was ₹12,682.43 crore. ET was the first to report on the sale on December 23. Advent is...
- Advent pips Blackstone, set to buy Suven Pharma for Rs 6300 crAnnouncement expected as early as Monday morning. Open offer if fully subscribed to could make it a $1 bn deal
- Advent closes in on Suven Pharma buyoutPromoters Venkateswarlu Jasti and his family split Suven Life Sciences in FY20, turning the CRAMS business into a separately listed company...
- Fosun taps big buyout funds for Gland PharmaBuyout firms Advent International, Baring Private Equity Asia (now owned by EQT), Bain Capital, Blackstone, Carlyle and KKR are among those...
- PE firm Advent names its India API, CDMO platform as Cohance LifesciencesThe US-based PE firm which is betting on India pharma, said that it intends to add more assets in the future with the vision to become one ...
- Advent buys controlling stake in Avra Labs for $100 millionThe transaction is Advent’s fifth investment in India over the past 12 months
- Indian API segment sees PE, strategic inflow nearly doubling in 2021Three private equity– led investment platforms have been created specifically targeting the API space, while at least half a dozen transact...
- Aurobindo Pharma to buy US animal health firm Cronus for Rs 420 crHyderabad-based Cronus is engaged in development, manufacturing and sale of veterinary pharmaceutical products and has a large exposure in ...
- ChrysCap to buy 30% in Corona Remedies for Rs 670 croreChrysCap has signed a deal to acquire 20% stake from PE firm Creador, which is an existing investor, and another 10% from promoters, two pe...
- Solara promoter, TPG plan to sell stake in companyThe company has seen a near five-fold jump in its share price, giving promoters Kumar and his partner KR Ravishankar an additional reason t...
- Carlyle in talks to buy big stake in former Mylan India CEO’s companyThrough Viyash, Carlyle plans to deploy about $300 million in India, sources said. Set up in 2019, Hyderabad-based Viyash is engaged in man...
- PE fund Creador to sell Corona Remedies stake; eyes Rs 2,400 cr valuationSpark Capital is advising the PE fund for the stake sale. The proposed deal is expected to value Corona at Rs.2000-2400 crore.
- Anthem Bio catches global buyout funds' eye, stake sale could see valuation rocket to $1 billionLaunched by ex-Biocon executive Ajay Bharadwaj, the Rs 1,200 crore Anthem Biosciences competes with Syngene International and GVK Bio. O3 C...
- PE fund Advent International buys controlling stake in API manufacturer RA Chem PharmaThe US private equity fund is understood to have pipped a rival offer from a consortium consisting another PE fund Carlyle Group and former...
- Advent joins race to buy Ra Chem from Micro LabsAdvent will compete with Carlyle that has teamed up with former Mylan Labs CEO Hari Babu, said multiple sources with knowledge of the matte...
Load More
